eflutinib

Eflutinib appears to be a name associated with a third-generation epidermal growth factor receptor (EGFR) inhibitor. These types of drugs are typically small molecules designed to target EGFR mutations, particularly the T790M resistance mutation, which can develop in non-small cell lung cancer (NSCLC) patients treated with earlier generations of EGFR tyrosine kinase inhibitors. While specific details regarding its developer, dedicated clinical trials, or unique identifiers are not readily available under this exact name, it is generally understood to function by inhibiting the EGFR signaling pathway to suppress tumor cell proliferation and induce apoptosis.